TherapeuticsMD Inc (TXMD) FinancialsTXMDFinancialTherapeuticsMD Inc

TherapeuticsMD Inc (TXMD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Mayne Pharma, accounting for 5951.5% of total sales, equivalent to $68.56M. Other significant revenue streams include Theramex and License revenue. Understanding this composition is critical for investors evaluating how TXMD navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, TherapeuticsMD Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -92.41%, while the net margin is 18.87%. These profitability ratios, combined with a Return on Equity (ROE) of -1.08%, provide a clear picture of how effectively TXMD converts its operational activities into shareholder value.

In the context of the broader market, TXMD competes directly with industry leaders such as ATOS and LTRN. With a market capitalization of $23.96M, it holds a significant position in the sector. When comparing efficiency, TXMD's gross margin of N/A stands against ATOS's N/A and LTRN's N/A. Such benchmarking helps identify whether TherapeuticsMD Inc is trading at a premium or discount relative to its financial performance.

The company has shown improved financial performance with a net income of $155,000 in Q2 2026, a significant recovery from previous losses. The gross margin remains strong at 100% for most quarters, indicating effective cost management in generating revenue.